Table 1:

HaploHCT Recipient Characteristics

			CD45RA-depleted haploHCT	Initial haploHCT	P value	Recent haploHCT	P value
Number			50	27		66
Age, yr (median, range)			8.1 (0.6–20.8)	11.9 (2.7–22.1)	0.269	12.7 (0.5–26.5)	0.227
Gender					0.81		1
	Female		19 (38%)	9 (33%)		25 (38%)
	Male		31 (62%)	18 (67%)		41 (62%)
Race					0.44		0.8
	Asian		2 (4%)	2 (7%)		2 (3%)
	Black		10 (20%)	7 (26%)		18 (27%)
	White		37 (74%)	16 (59%)		44 (67%)
	Other		1 (2%)	2 (7%)		2 (3%)
Ethnicity					0.45		0.43
	Hispanic		18 (36%)	7 (26%)		19 (29%)
	Non-Hispanic		32 (64%)	20 (74%)		47 (71%)
Diagnosis					0.044		0.048
	acute leukemia		47 (94%)	21 (78%)		48 (73%)
	lymphoma		1 (2%)	1 (4%)		5 (8%)
	MDS		2 (4%)	2 (7%)		8 (12%)
	JMML					3 (4%)
	CML			3 (11%)		2 (3%)
Disease status					0.15		0.53
	Standard		36 (72%)	24 (89%)		51 (77%)
		CR1	17	8		26
		CR2	14	10		9
		CR>2	3	3		8
		Other	2	3		8
	Refractory		14 (28%)	3 (11%)		15 (23%)
		PIF	8
		Relapse 1	4	1		10
		Relapse ≥2	2	1		2
		RAEB		1		3
Prior Autologous HCT			1 (2%)	1 (3.7%)	1.000	3 (4.5%)	0.63
Donor					0.76		0.580
	Father		17 (34%)	9 (33%)		28 (42%)
	Mother		29 (58%)	18 (67%)		32 (48%)
	Other related		1 (2%)			1 (2%)
	Sibling		3 (6%)			5 (8%)
	Unrelated
HLA mismatch (#/10)					1		1
	0
	1
	2		1 (2%)	1 (4%)		2 (3%)
	>2		49 (98%)	26 (96%)		64 (97%)
CD34+ cell dose (x106/kg)					0.029		0.023
	Median (range)		16.7(2.95–67.55)	10.4(1.5–39.0)		10.9(1.7–49.75)
CD3+ cell dose (x106/kg)					<0.001		<0.001
	Median (range)		75.85(16.1–528.6)	0.05(0.004–0.15)		0.05(0.01–0.25)